@article{JTD14761,
author = {Theodosios D. Filippatos and Moses S. Elisaf},
title = {Evacetrapib and cardiovascular outcomes: reasons for lack of efficacy},
journal = {Journal of Thoracic Disease},
volume = {9},
number = {8},
year = {2017},
keywords = {},
abstract = {Cholesteryl ester transfer protein (CETP) inhibitors are a drug class targeting the enzyme CETP (1). The first CETP inhibitor, torcetrapib, was discontinued because of increased cardiovascular events that were attributed to off-target adverse effects (increased aldosterone and blood pressure) (2).},
issn = {2077-6624}, url = {https://jtd.amegroups.org/article/view/14761}
}